See more : Exor N.V. (EXO.AS) Income Statement Analysis – Financial Results
Complete financial analysis of Aerpio Pharmaceuticals, Inc. (ARPO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aerpio Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- City Developments Limited (C09.SI) Income Statement Analysis – Financial Results
- Alchemy Creative, Inc. (ALMY) Income Statement Analysis – Financial Results
- Yü Group PLC (YU.L) Income Statement Analysis – Financial Results
- Norben Tea & Exports Limited (NORBTEAEXP.BO) Income Statement Analysis – Financial Results
- CHANGJIU HLDGS (6959.HK) Income Statement Analysis – Financial Results
Aerpio Pharmaceuticals, Inc. (ARPO)
About Aerpio Pharmaceuticals, Inc.
Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The company is headquartered in Blue Ash, Ohio and currently employs 27 full-time employees. The firm is focused on developing treatments for ocular disease. Its lead product candidate is AKB-9778. Its other two pipeline programs include AKB-4924 and ARP-1536. AKB-9778 is a small molecule activator of the Tie-2 pathway, which is being developed for the treatment of diabetic retinopathy (DR). AKB-4924 is a selective stabilizer of hypoxia-inducible factor-1 alpha (HIF-1alpha), which is being developed for the treatment of inflammatory bowel disease (IBD). ARP-1536 is a humanized monoclonal antibody directed at the same target as AKB-9778. ARP-1536 binds the extracellular domain of vascular endothelial protein tyrosine phosphatase (VE-PTP) inhibiting its ability to interact with Tie-2. As of April 14, 2017, the Company had completed a Phase II trial of AKB-9778 in 144 patients with diabetic macular edema. As of April 14, 2017, the Company had completed Phase Ia clinical trial in healthy volunteers for AKB-4924.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Revenue | 5.51M | 4.47M | 823.00K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 35.02M | 20.02M | 14.44M | 8.32M | 0.00 | 0.00 |
| Gross Profit | -29.51M | -15.54M | -13.62M | -8.32M | 0.00 | 0.00 |
| Gross Profit Ratio | -535.75% | -347.36% | -1,655.04% | 0.00% | 0.00% | 0.00% |
| Research & Development | 35.02M | 20.02M | 14.44M | 9.82M | 15.14M | 12.75M |
| General & Administrative | 7.44M | 8.28M | 7.97M | 8.16M | 2.52M | 2.71M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 1.50M | 1.40M | 1.37M |
| SG&A | 7.44M | 8.28M | 7.97M | 9.67M | 3.92M | 4.08M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 7.44M | 7.56M | 7.96M | 10.32M | 15.93M | 15.33M |
| Cost & Expenses | 42.45M | 27.57M | 22.40M | 18.64M | 15.93M | 15.33M |
| Interest Income | 29.00K | 59.00K | 600.00K | 835.00K | 768.00K | 202.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 892.00K | 1.17M | 1.11M | 1.35M | 1.35M | 1.53M |
| EBITDA | -36.05M | -22.65M | -20.47M | -16.64M | -9.54M | -13.92M |
| EBITDA Ratio | -654.58% | -506.33% | -2,487.61% | 0.00% | 0.00% | 0.00% |
| Operating Income | -36.95M | -23.82M | -21.59M | -17.99M | -10.89M | -15.46M |
| Operating Income Ratio | -670.77% | -532.45% | -2,622.96% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 29.00K | 667.00K | -594.00K | -1.49M | -5.81M | 330.00K |
| Income Before Tax | -36.92M | -23.16M | -22.18M | -19.48M | -16.70M | -15.13M |
| Income Before Tax Ratio | -670.24% | -517.55% | -2,695.14% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -36.92M | -23.16M | -22.18M | -19.48M | -16.70M | -15.13M |
| Net Income Ratio | -670.24% | -517.55% | -2,695.14% | 0.00% | 0.00% | 0.00% |
| EPS | -1.08 | -0.96 | -1.35 | -2.43 | -3.59 | -2.25 |
| EPS Diluted | -1.08 | -0.96 | -1.35 | -2.43 | -3.59 | -2.25 |
| Weighted Avg Shares Out | 34.29M | 24.10M | 16.42M | 7.64M | 4.65M | 6.74M |
| Weighted Avg Shares Out (Dil) | 34.29M | 24.10M | 16.42M | 8.01M | 4.65M | 6.74M |
ARPO Stock: 12 Things to Know About Aerpio Pharma as Analyst Upgrade Sends Shares Soaring
Which Penny Stocks Are Investors Buying Right Now? 7 For Your Watchlist
Aerpio Pharmaceuticals Stock Increases Over 45% Pre-Market: Why It Happened
Aerpio Provides Second Update on Aadi Bioscience Presentation at the ASCO 2021 Virtual Meeting
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Aerpio Pharmaceuticals, Inc. - ARPO
AERPIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Aerpio Pharmaceuticals, Inc. - ARPO
Aerpio Provides Update on Aadi Bioscience Presentation at the ASCO 2021 Virtual Meeting
SHAREHOLDER ALERT: WeissLaw LLP Investigates Aerpio Pharmaceuticals, Inc.
Aerpio Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Aerpio Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – ARPO
Aerpio Pharmaceuticals (ARPO) Stock: Over 55% Increase Explanation
Source: https://incomestatements.info
Category: Stock Reports